CA-TALKDESK
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, continues to make it faster and easier for organizations to take advantage of generative artificial intelligence (GenAI) to unlock powerful new efficiencies in the contact center. Accelerating its vision of autonomous customer experience (CX) and building on the recent announcement of Talkdesk Autopilot, the company introduced Talkdesk Autopilot for Healthcare, the next generation of its iconic virtual agent specifically developed to handle patient and member use cases. Talkdesk Autopilot for Healthcare was launched today at the Healthcare Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition.
Talkdesk Autopilot is available across chat and voice channels in the Talkdesk Healthcare Experience Cloud™, the company’s purpose-built platform that helps organizations create synchronized, personalized, and radically convenient experiences for healthcare patients, members, and caregivers. Talkdesk Autopilot for Healthcare supports the whole patient journey through healthcare-specific integrations, workflows, and GenAI models developed based on the company’s extensive experience with healthcare organizations. The result is a connected, intelligent patient and member assistant proficient in resolving consumers’ most common questions and needs.
While many call center automation solutions focus on deflecting callers to other online tools, Talkdesk Autopilot can perform tasks that patients request and seamlessly loop in human agents when necessary. The result is frictionless interactions and improved patient acquisition and loyalty.
Patients and members call or chat with their providers and health plans for many important reasons before and after clinical visits. Talkdesk Autopilot for Healthcare now automates an expanded set of use cases that support the whole patient journey — including new patient acquisition, making and managing appointments, completing PCI-compliant payments, finding a nearby clinic, and managing claims and prior authorizations. In addition to leveraging deep and direct integrations with Electronic Health Record (EHR) systems, the tool now integrates with digital triage and symptom-checking platforms, including Infermedica and Isabel Health. It connects with physician and location directories to help patients find the right provider and directs plan members to the best level of care.
Talkdesk has led the healthcare contact center market since 2021 by directly integrating with EHR systems. Talkdesk Healthcare Experience Cloud is available in the integration marketplaces for leading EHR platforms, including athenahealth, Epic, and Oracle Health (formerly Cerner). Today, Talkdesk announced support for multiple EHR systems for Talkdesk Healthcare Experience Cloud. Now, the purpose-built contact center solution for healthcare can read and update information from different EHRs for customers who may use distinct platforms for various contact centers, specialties, or facilities during a conversation for greater efficiency, accuracy, and personalization.
Supporting Quotes
Tiago Paiva, chief executive officer and founder of Talkdesk, said: “Talkdesk continues to invest in meeting healthcare organizations’ unique and important needs with purpose-built solutions and integrations. Combining the power of GenAI with deep and sophisticated healthcare workflows makes Talkdesk Autopilot for Healthcare a landmark innovation that helps fully resolve, not just deflect, the needs of patients and caregivers throughout their journey. We’re proud to work with great customers every day to deliver a better experience, reduce the burden on human staff, and deliver value to the entire healthcare system.”
Jeff Kaplan, vice president of Patient Access at Memorial Healthcare System, stated: “Our consumers increasingly expect convenience and ease when engaging with their healthcare provider. Talkdesk Autopilot for Healthcare has helped us automate common patient calls and chats, freeing our staff to focus on helping our patients and families with the most complex needs. AI has amazing potential to help healthcare, but it’s critical to partner with vendors who understand the industry and can collaborate to build solutions to fit its unique requirements. We’re excited to continue to innovate with Talkdesk.”
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312839589/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom